Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I. (Q30449130)

21 June 2017

1 reference

title

Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I. (English)

1 reference

attention deficit hyperactivity disorder

21 June 2017

1 reference

0 references

author name string

Richard Lawrence Merkel

series ordinal

1

1 reference

PubMed ID

19785509

21 June 2017

Ajay Kuchibhatla

series ordinal

2

1 reference

PubMed ID

19785509

21 June 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

Expert Opinion on Drug Safety

21 June 2017

1 reference

21 June 2017

8

1 reference

21 June 2017

6

1 reference

21 June 2017

655-668

1 reference

Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder

21 June 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Long-term effects of stimulant medications on the brain: possible relevance to the treatment of attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Safety and tolerability of methylphenidate in preschool children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Long-term safety of stimulant medications used to treat children with ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

A post hoc analysis of d-threo-methylphenidate hydrochloride (focalin) versus d,l-threo-methylphenidate hydrochloride (ritalin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes' analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Randomized trial of a home-based family intervention for children who have deliberately poisoned themselves.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Psychostimulants in preschool children with attention-deficit/hyperactivity disorder: clinical evidence from a developmental disorders institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Developmental aspects of psychostimulant treatment in children and adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Hyperactive boys almost grown up. I. Psychiatric status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Young adult outcome of hyperactive children who received long-term stimulant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Adverse side effects of methylphenidate among mentally retarded children with ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Characteristics and motives of college students who engage in nonmedical use of methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Trends and college-level characteristics associated with the non-medical use of prescription drugs among US college students from 1993 to 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Misperceptions of non-medical prescription drug use: a web survey of college students.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Medical use, illicit use, and diversion of abusable prescription drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Prescription drug abuse and diversion among adolescents in a southeast Michigan school district.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Attention deficit hyperactivity disorder and substance use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

The Effect of Stimulant Treatment for ADHD on Later Substance Abuse and the Potential for Medication Misuse, Abuse, and Diversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Long-term treatment of children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

3-Year Follow-up of the NIMH MTA Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

Delinquent Behavior and Emerging Substance Use in the MTA at 36 Months: Prevalence, Course, and Treatment Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903279956

10.1517/14740330903279956

21 January 2018

Identifiers

DOI

1 reference

21 June 2017

1 reference

PubMed ID

19785509